MSD Pipeline

Q2 2023 Reflecting Pipeline to August 2, 2023
The chart below reflects the company’s research pipeline as of August 2, 2023. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.
# MSD pipeline as of August 2, 2023

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda

Moved forward since last pipeline update.

<table>
<thead>
<tr>
<th>Phase 2</th>
<th>Phase 2</th>
<th>Phase 2</th>
<th>Phase 2</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer NSCLC MK-0482</td>
<td>Hypercholesterolemia MK-0616</td>
<td>Cancer NSCLC quavonlimab MK-1308</td>
<td>Cancer CRC Hepatocellular Melanoma SCLC quavonlimab + pembrolizumab MK-1308A</td>
<td>Treatment Resistant Depression MK-1942</td>
</tr>
<tr>
<td>Thrombosis MK-2060</td>
<td>Cancer Bladder Breast Gastric Heme NSCLC Ovarian Pancreas zilovertamab vedotin MK-2140</td>
<td>Cancer Advanced solid tumors Prostate KEYTRUDA® MK-3475</td>
<td>Cancer Myeloproliferative Disorders bemedemstat MK-3543</td>
<td></td>
</tr>
<tr>
<td>Cancer NSCLC favezelimab MK-4280</td>
<td>Cancer Bladder Esophageal Melanoma RCC SCLC favezelimab + pembrolizumab MK-4280A</td>
<td>Cancer CRC Esophageal Melanoma NSCLC Ovarian RCC SCLC MK-4830</td>
<td>Pulmonary Arterial Hypertension MK-5475</td>
<td>Cancer Prostate MK-5684</td>
</tr>
</tbody>
</table>

1. 3
## MSD pipeline as of August 2, 2023

### Phase 2

<table>
<thead>
<tr>
<th>Cancer NSCLC</th>
<th>NASH Efinopegdu tide</th>
<th>Cancer Biliary CRC Endometrial Esophageal HCC Pancreatic Rare cancers Certain VHL tumors (EU)</th>
<th>Cancer Advanced Solid Tumors Biliary Bladder Cervical Endometrial Gastric HCC NSCLC TUKYSA® MK-7119</th>
<th>Ulcerative Colitis MK-7240</th>
</tr>
</thead>
</table>

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda.
3. Being developed as monotherapy and/or in combination with Keytruda.
4. On FDA clinical hold.
5. On partial clinical hold for higher doses than those used in current clinical trials.
6. Phase 2b development costs are being co-funded.

**Moved forward since last pipeline update.**

### Cancer

- Advanced solid tumors
- LYNPARZA® MK-7339

### Cancer

- Biliary CRC Endometrial Esophageal HCC Pancreatic Rare cancers Certain VHL tumors (EU)
- WELIREG™ MK-6024

### Cancer

- Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric Heme HNSCC HCC Ovarian Prostate SCLC
- VIBOSTOLIMAB™ MK-7684A

### Cancer

- Biliary Bladder Cervical Endometrial Gastric HCC NSCLC
- TUKYSA® MK-7119

### Cancer

- Advanced Solid Tumors
- Biliary Bladder Cervical Endometrial Gastric NSCLC
- TUKYSA® MK-7119

### Cancer

- Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric Heme HNSCC HCC Ovarian Prostate SCLC
- LENVIMA® MK-7902

### Cancer

- Pulmonary Hypertension due to Left Heart Disease
- Sotatercept MK-7962

### Schizophrenia

- MK-8189

### HIV-1 Infection

- Islatravir+MK-8507 MK-8591B

### HIV-1 Infection

- Islatravir+lenacapavir MK-8591D

### Dengue fever virus Vaccine

- V181
# MSD pipeline as of August 2, 2023

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda
4. On partial clinical hold for higher doses than those used in current clinical trials
5. Available in the U.S. under Emergency Use Authorization

Moved forward since last pipeline update.

<table>
<thead>
<tr>
<th>Phase 3</th>
<th>Phase 3</th>
<th>Phase 3</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer</strong>&lt;br&gt;Heme&lt;br&gt;nemtabrutinib&lt;br&gt;MK-1026</td>
<td><strong>Cancer</strong>&lt;br&gt;RCC&lt;br&gt;quavonlimab + pembrolizumab&lt;br&gt;MK-1308A</td>
<td><strong>Respiratory</strong>&lt;br&gt;syncytial virus&lt;br&gt;clesrovimab&lt;br&gt;MK-1654</td>
<td><strong>Cancer</strong>&lt;br&gt;Cutaneous Squamous Cell Carcinoma&lt;br&gt;(EU)&lt;br&gt;Hepatocellular (EU)&lt;br&gt;Mesothelioma&lt;br&gt;Ovarian&lt;br&gt;SCLC&lt;br&gt;KEYTRUDA®&lt;br&gt;MK-3475</td>
</tr>
<tr>
<td><strong>Cancer</strong>&lt;br&gt;NSCLC&lt;br&gt;pembrolizumab + hyaluronidase&lt;br&gt;subcutaneous&lt;br&gt;MK-3475A</td>
<td><strong>Cancer</strong>&lt;br&gt;CRC&lt;br&gt;Heme&lt;br&gt;favezelimab + pembrolizumab&lt;br&gt;MK-4280A</td>
<td><strong>Anti-Viral</strong>&lt;br&gt;COVID-19&lt;br&gt;molnupiravir&lt;br&gt;MK-4482&lt;sup&gt;1,5&lt;/sup&gt;&lt;br&gt;(US)</td>
<td><strong>Cancer</strong>&lt;br&gt;RCC&lt;br&gt;WELIREG™&lt;br&gt;MK-6482&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Cancer</strong>&lt;br&gt;Breast&lt;br&gt;CRC&lt;br&gt;TUKYSA®&lt;br&gt;MK-7119&lt;sup&gt;1&lt;/sup&gt;</td>
<td><strong>Cancer</strong>&lt;br&gt;NSCLC&lt;br&gt;SCLC&lt;br&gt;LYNPARZA®&lt;br&gt;MK-7339&lt;sup&gt;2&lt;/sup&gt;</td>
<td><strong>Cancer</strong>&lt;br&gt;Melanoma&lt;br&gt;NSCLC&lt;br&gt;SCLC&lt;br&gt;vibostolimab + pembrolizumab&lt;br&gt;MK-7684A</td>
<td><strong>Cancer</strong>&lt;br&gt;Esophageal&lt;br&gt;Gastric&lt;br&gt;HNSCC&lt;br&gt;NSCLC&lt;br&gt;LENVIMA®&lt;br&gt;MK-7902&lt;sup&gt;1,2&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Pulmonary Arterial Hypertension</strong>&lt;br&gt;sotatercept&lt;br&gt;MK-7962</td>
<td><strong>HIV-1 infection</strong>&lt;br&gt;doravirine + islatravir&lt;br&gt;MK-8591A&lt;sup&gt;4&lt;/sup&gt;</td>
<td><strong>Pneumococcal Vaccine</strong>&lt;br&gt;Adult&lt;br&gt;V116</td>
<td><strong>Cancer</strong>&lt;br&gt;Melanoma&lt;br&gt;V940&lt;sup&gt;1,2&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
## MSD pipeline as of August 2, 2023

### New Molecular Entities Under Review

- Cough gefapixant MK-7264 (US, EU)

### Certain Supplemental Filings Under Review

<table>
<thead>
<tr>
<th>1L Advanced or Unresectable Biliary Tract Cancer (KN966) KEYTRUDA® MK-3475 (US, EU, JPN)</th>
<th>2L Hepatocellular Cancer (KN394) KEYTRUDA® MK-3475 (US)</th>
<th>Resectable Stage II, IIIA or IIIB NSCLC or IIIIB NSCLC KEYTRUDA® MK-3475 (US)</th>
<th>Metastatic HER2+ Gastric Cancer (KN811) KEYTRUDA MK-3475 (EU)</th>
</tr>
</thead>
</table>

| Locally Advanced or Metastatic Merkel Cell Carcinoma (KN913) KEYTRUDA® MK-3475 (US) | Metastatic 1L prostate cancer (PROpel) LYNPARZA® MK-7339 (JPN) | 1L HER2 negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KN859) KEYTRUDA® MK-3475 (US, EU, JPN) | Adjuvant NSCLC (KN091) KEYTRUDA® MK-3475 (EU) |

1. Being developed in a collaboration
2. In July 2023, the FDA accepted MSD’s resubmission of the NDA for gefapixant following the Company’s response to the CRL received in January 2022.

- Moved forward since last pipeline update.
## MSD pipeline as of August 2, 2023

1. Approvals obtained within the last 3 months.
2. Being developed in a collaboration
3. Moved forward since last pipeline update.

<table>
<thead>
<tr>
<th>New Molecular Entities Approvals(^1)</th>
<th>Certain Supplemental Approvals(^1)</th>
<th>Certain Supplemental Approvals(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurofibromatosis type-1 Pediatric KOSELUGO® MK-5618(^2) (CHN)</td>
<td>Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma (KN170/KNA33) KEYTRUDA® MK-3475 (JPN)</td>
<td>Prophylaxis of CMW in kidney transplant patients PREVYMIS™ MK-8228 (US)</td>
</tr>
<tr>
<td></td>
<td>BRCA-mutated Metastatic Castration-Resistant Prostate Cancer (PR0pel) LYNPARZA® MK-7339(^2) (US)</td>
<td>Pneumococcal Infection for pediatric use VAXNEUVANCE™ V114 (JPN)</td>
</tr>
</tbody>
</table>
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in the presentation set forth below was current as of August 2, 2023. While this presentation remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after August 2, 2023.

The chart reflects the MSD research pipeline as of August 2, 2023.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.